RankAlpha logo
Back to Rankings

MDCX

MedicusF
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
Multiple clinical programs, regulatory authorizations and Pfizer's expected continued involvement in CD228V provide several potential validation paths. Successful trial execution or clearer partner-funded development could be material relative to MDCX's approximately $16.4 million market capitalization.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
Equity, ATM or debt financing could dilute shareholders or add restrictive financing costs.
Momentum
11
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.17 · Bull $0.32 · Bear $0.07Analysis 2026-09-11; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-27 • Vendor: Data Vendor v1
Scores
As of 2026-10-27 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-11 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-10-27

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-27. Definitions

Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $203.75
Why
Momentum11 · Δ7d -
Value41 · Δ7d -0.1
Sentiment0 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.

Confirming evidence

  • • Value remains the lead driver in the composite, 7D delta -0.1.

Contradictions & invalidation

  • • Equity, ATM or debt financing could dilute shareholders or add restrictive financing costs.
  • • Micro-cap liquidity and event-driven volatility can produce price moves disconnected from fundamental value.
  • • MDCX remains a loss-making micro-cap biotechnology issuer with substantial clinical uncertainty.

Catalyst clock

2026-11-15

Cash runway and dilution checkpoint

Lead driver: Value · See fundamentals
Momentum
11
8% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.3
Sentiment
0
45% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade F. Momentum 10.9 / Value 40.6 / Sentiment 0.0

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-11. Scenario method

B+
Bull case
25%
Probability
Target price
$0.32
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
Most likely
B
Base case
45%
Probability
Target price
$0.17
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.07
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-10-27
Market Cap
$4.64M
Beta
-
Shares Out
22.03M
P/E (TTM) · Derived
-0.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.28
Rev YoY
-
EPS YoY
-51.2%
Gross Margin
-
Op Margin
-
Net Debt
-$2.36M
Current Ratio
1.57
As of 2026-10-27 • Updated nightlySource: Internal modelMethods & Data